Supplementary B: Results from Reporting Quality Assessment

Q1. Reported aim/hypothesis clearly
Q2. Interventions described
Q3. Definition of FAI
Q4. Describes study design
Q5. Reports sampling frame
Q6. Reports inclusion criteria
Q7. Reports participation rate
Q8. Reports participant characteristics
Q9. Participant dropouts described
Q10. Intervention adverse events reported
Q11. Intervention co-variants reported
Q12. Statistical methods described
Q13. Main findings described
Q14. Random variability reported
Q15. Statistical parameters reported
Q16. Sample size calculation reported
Q17. Comparability of reference group
Q18. Adequate participation rate
Q19. Recruitment period described
Q20. Participant losses taken into account
Q21. Reliability of FAI assessment
Q22. Standardised assessment of FAI
Q23. Reliability of 3D Biomechanics
Q24. Standardised assessment of 3D Biomechanics
Q25. Assessment period conducted at the same time
Q26. Collected data on severity/symptoms
Q27. Adjusted for co-variants/confounders
Q28. Sufficient follow-up timeframes
Q29. Lengths of follow-up taken into account
Q30. Data reported in subgroups
Q31. Generalizability to the eligible population (participation rate)
Q32. Generalizability to the eligible population (random sampling)

Quality H=High, M=Moderate, L=Low

Studies scoring "Yes" (%)

| Study                          | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | Q14 | Q15 | Q16 | Q17 | Q18 | Q19 | Q20 | Q21 | Q22 | Q23 | Q24 | Q25 | Q26 | Q27 | Q28 | Q29 | Q30 | Q31 | Q32 | Overall Score |
|-------------------------------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----------------|
| Bagwell et al, 2016           |   | 0  |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    | 0.33 |
| Diamond et al, 2016           |   | 0  |    |    | 0  |    |    |    | 0  |    | 0  |    |    |    |    | 0  |    | 0  |    | 0  | 0  | 0  |    | 0  |    | 0  |    | 0  |    | 0.33 |
| Hammond et al, 2017           |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Hetsroni et al, 2015          |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Hunt et al, 2013              |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Kennedy et al, 2009           |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Kumar et al, 2014             |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Lamontagne et al, 2009        |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Ng et al, 2015                |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Samaan et al, 2016            |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Samaan et al, 2016            |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Brisson et al, 2013           |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Lamontagne et al, 2011        |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |
| Rylander et al, 2013          |   | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0.33 |

Average score (0-2)

Studies scoring "Yes": 100
Studies scoring "Partial": 50
Studies scoring "No" or "Unable to Determine": 0

Not Applicable: Item removed from scoring and not included in the percentage calculations.